SciELO - Scientific Electronic Library Online

 
vol.33 número3Analysis of oxidative status and biochemical parameters in adult patients with sickle cell anemia treated with hydroxyurea, Ceará, BrazilThe role of natural killer cells in chronic myeloid leukemia índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Revista Brasileira de Hematologia e Hemoterapia

versión impresa ISSN 1516-8484

Resumen

MACHADO, Melissa Pereira et al. Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response. Rev. Bras. Hematol. Hemoter. [online]. 2011, vol.33, n.3, pp. 211-215. ISSN 1516-8484.  http://dx.doi.org/10.5581/1516-8484.20110056.

BACKGROUND: Real time PCR has become the most common technique to monitor BCR-ABL transcript levels of patients treated with kinase inhibitors. The aim of this study was to evaluate BCR-ABL levels of chronic myeloid leukemia patients treated with imatinib in the chronic phase and correlate the response to therapy and event-free survival. METHODS: BCR-ABL levels were measured in peripheral blood cell samples using Real time PCR at diagnosis and then every 3 months after starting therapy with imatinib. Major molecular response was defined as a three-log reduction from the standardized baseline value. Major molecular response values were adjusted to international scale using a conversion factor of 1.19. The results are reported as a BCR-ABL/ABL ratio (%). RESULTS: Hematological, major cytogenetic and complete cytogenetic responses were achieved by 57 (95%), 45 (75%) and 38 (63%) patients, respectively. Twenty-four out of sixty patients achieved a major molecular response (40%) in a median time of 8.5 months. Overall survival and event free survival were higher for patients with (100%) versus patients without (77%) a complete cytogenetic response (p-value = 0.01) at 48 months. Patients with complete cytogenetic response and major molecular response had a higher event free survival compared to patients with complete cytogenetic response but without major molecular response (p-value = 0.007). CONCLUSION: In conclusion, the prognostic impact of achieving complete cytogenetic response and a major molecular response and also the importance of molecular monitoring in the follow-up of chronic myeloid leukemia patients were demonstrated.

Palabras llave : Polymerase chain reaction; Monitoring; Leukemia, myelogenous, chronic, BCR-ABL positive.

        · texto en Inglés     · pdf en Inglés